RESUMEN
Nalidixic acid, a new chemotherapeutic agent, has been shown to possess considerable in vitro activity against a variety of Gram-negative organisms. It has been used effectively in the treatment of urinary tract infections caused by Gram-negative organisms. This study was conducted to investigate the therapeutic effect of nalidixic acid on diarrheas and on urinary tract infections in children. A total of 51 cases of diarrhea were given nalidixic acid at a dosage of 25 mg. per pound of body weight. Of these, 82.5 per cent responded favorably to treatment. Ten patients with urinary tract infections, 8 of whom had been treated previously with antimicrobial agents without response were given nalidixic acid. All ten cases responsed favorably to nalidixic acid therapy. No side-effects were noted with the use of this chemotherapeutic agentNalidixic acid is an effective chemotherapeutic agent against infections caused by Gram-negative organisms particularly urinary tract infections and acute diarrheal disorders. (Summary and Conclusions)
RESUMEN
A practical etiological classification of infantile diarrheas, with reference to treatment, is givenA method of treatment of moderate and severe infantile diarrheas with planned, continuous, intravenous replacement and maintenance of fluid and electrolyte requirements, and the correction of acidosis by alkalinizing agents is outlinedA regimen of treament of mild diarrheas by oral medication is described.(Summary)
RESUMEN
sulfadimethroxine, known commercially as Madribon, was tried in 104 cases of acute infections of the respirtory and gastro-intestinal tract in infants and children. The dose employed ranged from 30-50 mg/kg. body weight as the single initial dose and 10-25 mg/kg. body weight as the daily single maintenance dose for three to fours days in order to evaluate its therapeutic efficacy. Of the 104 cases, 74.1 or 75 percent responded favorably within a reasonable time (excellent, good, fair) and 25 or 26.8 percent failed to respond favorably. The failures were in the pneumonias in which eleven out of the 40 cases or 27.5 percent reacted poorly, and in the acute diaarrheas where 10 out of the 36 cases or 27.7 percent, failed to respond to the treatment. One case developed mild urticaria. (Summary)
RESUMEN
We have presented two cases of giant cell hepatitis from the Santo Tomas University Hospital Charity Service which have occurred within a ten-year period (1953-1962), and have compared the incidence of this condition experienced locally to other series reported from abroad. A brief review of the literature is presentedThe summary of the clinical and pathologic aspects is also given. The differential diagnosis between neonatal hepatitis and biliary atresia is often difficult to make even when liver biopsy is performed because the histologic picture is similar in both conditions. The recommended diagnostic procedures include an open liver biopsy followed by cholangiographyPresently the concensus is that giant cell reaction of the liver is a non-specific phenomenon, probably representing a response to diffuse injury of the fetal and neonatal liver. Therefore, this condition is a morphologic or pathologic entity rather than a clinical oneSince the etiology and pathogenesis of giant-cell hepatitis is still poorly understood, the therapeutic measures remain symptomatic and often unsatisfactory. (Summary and Conclusion)
RESUMEN
A new long-acting sulfonamide, sulfadimethoxine (Madribon) was tried in 43 cases of acute infections of the respiratory tract and the gastrointestinal tract in infants and children. When a dose of 20 mg./Kg. body weight as initial dose and 10 mg./Kg. body weight as maintenance dose, as recommended by European authors, was employed, seven or 41.06 per cent of 17 cases responded favorably and ten or 59 per cent did not show any clinical response. When the dose was increased to 30 mg./Kg. body weight as initial dose and 15 mg./Kg. body weight per day as maintenance dose in infants, 21 out of 23 patients showed definite clinical response. Similar results were obtained in children. The drug was well tolerated and did not give rise to gastrointestinal disturbances, and only one case developed a mild rash. (Summary)
RESUMEN
A long-acting ACTH Gel preparation has been used in 19 cases of tuberculosis in infants and young children who had already received the standard antituberculosis treatment. In 17 of the nineteen cases the addition of ACTH to the therapy produced definite improvement which contributed to shortening the course of the diseaseFrom this study, we may conclude that ACTH given in a long-acting form, in single injections daily or every other day, together with the usual antimicrobial therapy, is a useful weapon to combat the toxic manifestations of primary tuberculosis or to increase the therapeutic efficacy of the antimicrobial drugs. Used in periods of not more than two weeks, the side-effects are minimal. (Summary and Conclusion)